IPSIndian Journal of Pharmacology
Home  IPS  Feedback Subscribe Top cited articles Login 
Users Online : 472 
Small font sizeDefault font sizeIncrease font size
Navigate Here
  Search
 
  
Resource Links
   Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
   Article in PDF (336 KB)
   Citation Manager
   Access Statistics
   Reader Comments
   Email Alert *
   Add to My List *
* Registration required (free)

 
In This Article
   References

 Article Access Statistics
    Viewed450    
    Printed20    
    Emailed0    
    PDF Downloaded22    
    Comments [Add]    

Recommend this journal

 


 
 Table of Contents    
LETTER TO THE EDITOR
Year : 2022  |  Volume : 54  |  Issue : 6  |  Page : 462-463
 

Intradermal versus intramuscular COVID-19 vaccination aiming at protection for delta variant: cost utility analysis


1 Private Academic Consultant, Bangkok, Thailand
2 Department of Community Medicine, Dr. D. Y. Patil Vidhyapeeth, Pune, Maharashtra, India

Date of Submission16-Apr-2022
Date of Decision20-Aug-2022
Date of Acceptance08-Dec-2022
Date of Web Publication31-Jan-2023

Correspondence Address:
Rujittika Mungmunpuntipantip
Private Academic Consultant, 111 Bangkok 122 Bangkok 103300
Thailand
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/ijp.ijp_271_22

Rights and Permissions



How to cite this article:
Mungmunpuntipantip R, Wiwanitkit V. Intradermal versus intramuscular COVID-19 vaccination aiming at protection for delta variant: cost utility analysis. Indian J Pharmacol 2022;54:462-3

How to cite this URL:
Mungmunpuntipantip R, Wiwanitkit V. Intradermal versus intramuscular COVID-19 vaccination aiming at protection for delta variant: cost utility analysis. Indian J Pharmacol [serial online] 2022 [cited 2023 Mar 21];54:462-3. Available from: https://www.ijp-online.com/text.asp?2022/54/6/462/368837




Sir,

Coronavirus disease 2019 (COVID-19) remains a big global problem and no effective method is yet available for disease containment.[1] One of the possible good approaches for the management COVID-19 pandemic crisis is using the COVID-19 vaccine.[2] Mass COVID-19 vaccination is now accepted as the best option for containment of the disease outbreak. Vaccine inoculation is a good medical preventive manipulation against the new viral disease. COVID-19 immunization is widely used and its efficacy for disease prevention is proposed. In general practice, overall two doses of COVID-19 vaccines are given to the vaccine recipient. There are two intramuscular vaccination doses required. By giving the COVID-19 vaccine to the vaccine recipient in a different way, many scientists have given ideas for risk reduction and given the solution to the insufficient vaccine supply situation. The novel choice of COVID-19 immunization's cost, usefulness, and safety are all important aspects to consider. In this study, the authors performed a medical economics study aiming at comparing the cost per utility of various options of vaccination. The new intradermal COVID-19 vaccine administration as well as the classical technique, intramuscular administration, are evaluated.

The authors used a cost-utility analysis in this study. The technique is used for examining the cost and utility of the vaccination. The COVID-19 vaccines that will be offered to the general population are focused on and evaluated. The cost is calculated based on publicly accessible information, as was already said. The stated vaccine efficacy from the earlier comparison trial is mentioned in terms of utility. The usefulness is defined as the titer of neutralizing antibodies at 1 month after getting the COVID-19 vaccine. Based on the referring report, the utility of alternative intradermal and normal intramuscular COVID-19 vaccine injection is 353% and 563%, orderly.[3] Publicly available data have already been mentioned as the main source of the study. In the analysis, the data on vaccination cost, which is publicly accessible, are categorized as a cost. In this study, the suggested vaccine efficacy is hereby categorized as a utility. The required cost for the utility of each studied immunization approach is assessed.

The unit cost per unit utility in case that intradermal COVID-19 vaccine immunization technique is employed is lower according to cost-utility analysis (0.019 vs. 0.061 Euro for intradermal vs. intramuscular). The medical economics approach is used in this work for analyzing the cost and utility of the new immunization methods. The price of immunization is hereby set as cost, whereas the observed efficacy of vaccination after giving it to the vaccine recipient is assigned as utility for the present study. Each vaccine injection's cost per utility is found, then the comparison between derived cost per utility value of the technique is done. Adverse effect after immunization is another important concern. It can show that immunization techniques that can provide a safe clinical outcome at with a lower cost should be more favorable. Based on this study, the cost per utility for protection against the delta variant from intradermal vaccination is 3.21 times lower than that of intramuscular vaccination. It might be wise to implement intradermal COVID-19 vaccine policy aiming at protection for the delta variant.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.



 
  References Top

1.
Hsia W. Emerging new coronavirus infection in Wuhan, China: Situation in early 2020. Case Study Case Rep 2020;10:8-9.  Back to cited text no. 1
    
2.
Soleimanpour S, Yaghoubi A. COVID-19 vaccine: Where are we now and where should we go? Expert Rev Vaccines 2021;20:23-44.  Back to cited text no. 2
    
3.
Intapiboon P, Seepathomnarong P, Ongarj J, Surasombatpattana S, Uppanisakorn S, Mahasirimongkol S, et al. Immunogenicity and safety of an intradermal BNT162b2 mRNA vaccine booster after two doses of inactivated SARS-CoV-2 vaccine in healthy population. Vaccines (Basel) 2021;9:1375.  Back to cited text no. 3
    




 

Top
Print this article  Email this article
 

    

Site Map | Home | Contact Us | Feedback | Copyright and Disclaimer | Privacy Notice
Online since 20th July '04
Published by Wolters Kluwer - Medknow